Obsidian Therapeutics, Inc. - 10-Q Filing

Obsidian Therapeutics reports quarterly results for the period ended September 30, 2026, highlighting ongoing R&D and administrative expenditures.

SEC EDGAR ·

Tickers: $OBX

Read the full article at SEC EDGAR

More Regulatory news